top of page

Celogics highlights its iPSC derived Cardiomyocytes at 2022 SOT Annual Meeting and Tox Expo

Updated: Feb 1, 2023

Published DATE: April 20th, 2022

Seattle, WA., April 20th, 2022 - Celogics, a leading developer in iPSC derived Cardiomyocytes, showcased their unique high-quality cells during the Society of Toxicology (SOT) Annual Meeting and ToxExpo in San Diego, California from March 27-31, 2022.

Celo.Cardiomyocytes are high-quality human iPSC-derived cardiomyocytes developed by NEXEL, well known as Cardiosight-S, and exclusively licensed to Celogics for global distribution. These cells are derived from induced Pluripotent Stem Cells (iPSCs) using proprietary protocols which optimize the user experience by prioritizing purity, reproducibility, and electrophysiology.

“Increasingly, the use of iPSC derived cells and tissues is a must-have during every stage of the drug discovery pipeline." said Jin Chang, Chief Operating Officer of Celogics. "Our unique innovations bring new levels of precision and consistency to in vitro biology, to accelerate development of safer, more effective treatments."

Celogics plans to continue to build its pipeline fully able to manufacture different kinds of iPSC-derived cell products to US and global markets. Currently, Celogics is focused on the development of skeletal myocytes, following up with the new optimized 3D culture & tissue-engineering application use Celo.Cardiomyocytes 3D Media.

For more information, please visit or follow the company on Twitter @celogics or LinkedIn

83 views0 comments


bottom of page